MeRes100 Bioresorbable Vascular Scaffold

The MeRes100™ scaffold's 100-micron strut thickness facilitates improved acute lumen gain and endothelialization due to minimized vessel wall injury and reduced flow disturbance. Studies demonstrate a correlation between thinner struts and reduced late lumen loss, thereby improving long-term clinical outcomes such as target lesion revascularization (TLR).

The MeRes100™ scaffold utilizes PLLA, a bioresorbable polymer that undergoes hydrolysis into L-lactic acid. This process ensures complete scaffold resorption within approximately 24 months. The controlled degradation minimizes chronic inflammation and late adverse events like scaffold thrombosis compared to permanent metallic stents.

The MeRes100™ scaffold offers improved conformability and deliverability due to its PLLA material and optimized design. Its bioresorbable nature eliminates long-term caging of the vessel, allowing for vasomotion, late vessel remodeling, and potential for future surgical or percutaneous interventions at the same site.

This product is manufactured by Meril Life Sciences and is distributed by Agile Healthcare across all districts of Telangana.

Yes, all Meril Life Sciences products distributed by Agile Healthcare, including the MeRes100 Bioresorbable Vascular Scaffold, strictly adhere to CDSCO guidelines and ISO 13485:2016 quality standards.

The MeRes100 Bioresorbable Vascular Scaffold is constructed using PLLA (Poly-L-Lactic Acid), ensuring high biocompatibility and durability.